Myriad Genetics
MYGN
198 hedge funds and large institutions have $1.45B invested in Myriad Genetics in 2022 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 72 increasing their positions, 65 reducing their positions, and 24 closing their positions.
446% more call options, than puts
Call options by funds: $4.9M | Put options by funds: $897K
11% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 65
0.87% more ownership
Funds ownership: 98.56% → 99.43% (+0.87%)
8% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 24
3% less funds holding
Funds holding: 205 → 198 (-7)
27% less capital invested
Capital invested by funds: $1.98B → $1.45B (-$530M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$31.1M |
| 2 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$22.1M |
| 3 |
State Street
Boston,
Massachusetts
|
+$12.6M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$8.02M |
| 5 |
SEI Investments
Oaks,
Pennsylvania
|
+$6.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$14.6M |
| 2 |
JP Morgan Chase
New York
|
-$10.2M |
| 3 |
Millennium Management
New York
|
-$7.16M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$5.94M |
| 5 |
Man Group
London,
United Kingdom
|
-$5.65M |
MYGN Hedge Fund Activity: Q2 2022 in Review
198 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q2 2022, worth a combined $1.45B — down 27% from $1.98B a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of MYGN and 22 opened new positions — a net loss of 2 holders — while 65 trimmed existing stakes and 72 added.
The largest buyer was Camber Capital Management, adding an estimated $31.1M. The largest seller was PFM Health Sciences, cutting an estimated $14.6M.
- 198 institutional investors held Myriad Genetics (MYGN) as of Q2 2022, down from 205 in Q1 2022.
- Funds reported $1.45B of Myriad Genetics stock for Q2 2022, down 27% quarter-over-quarter.
- 22 funds opened new Myriad Genetics positions in Q2 2022 and 24 closed out, a net change of -2 holders.
- The largest Myriad Genetics buyer in Q2 2022 was Camber Capital Management, an estimated $31.1M added.
- The largest Myriad Genetics seller in Q2 2022 was PFM Health Sciences, an estimated $14.6M sold.
Based on aggregated 13F filings for Q2 2022.